[BrainLife] Treatment

Treatment

Treatment Surveys
	Treatment Surveys


Surgery
	Surgery of Low Grade Gliomas
	Surgery of Metastatic Tumors
	Surgery of Pediatric Brain Tumors
	Surgical Neuro-Oncology


Radiation Therapy
	Boron Neutron Capture Therapy
	Brachytherapy
	Radiation-Enhancing Agents
	Radioimmunotherapy
	Radiosurgery
	Radiotherapy


Chemotherapy
	Chemotherapy Surveys	Lomustine (CCNU)
	BMS-247550	Marimastat
	Busulfan	Melphalan
	Bleomycin	Methotrexate
	Capecitabine (Xeloda)	Methylprednisolone
	Carboplatin (CBDCA)	Mitoxantrone
	Carmustine (BCNU)	Nimustine (ACNU)
	Chemotherapy-Enhancing Agents	Oxaliplatin
	Chemotherapy Timing	Paclitaxel (Taxol)
	Cisplatin (CDDP)	PCV (Procarbazine, Lomustine, and Vincristine)
	Cloretazine	Prednisone
	Cyclophosphamide	Procarbazine (PCB)
	Cytarabine (Ara-C)	Pyrazoloacridine
	Dacarbazine	Ranimustine (MCNU)
	Daunorubicin	SI-27
	Docetaxel (Taxotere)	ST1481 (Gimatecan)
	Doxorubicin (Caelyx)	Temozolomide Clinical Trials (Temodar, Temodal)
	Fluorouracil	Temozolomide Investigations
	Fotemustine	Teniposide (VM26)
	Gemcitabine	Thiotepa
	Glufosfamide	Topotecan and Camptothecin analogues
	Hydroxyurea	VCP (Vincristine, Lomustine, and Prednisone)
	Ifosfamide	Vinblastine
	Indomethacin	Vincristine
	Irinotecan (CPT-11)	Vinorelbine



"New" Treatment Agents
	Antibodies	Phelynbutyrate
	Bevacizumab	Poly-ICLC
	Bortezomib (Velcade)	Rapamycin (Rapamune)
	Cabergoline	Retinoids (Accutane, Fenretinide, etc.)
	CCI-779	Rituximab
	Cetuximab (EGFR inhibitor)	Riluzole
	Cimetidine	R115777 (Zarnestra)
	Clomipramine	Suberoylanilide Hydroxamic Acid (SAHA)
	CpG-ODN	STI571 (Gleevec, Imatinib)
	Dexamethasone	Surgifoam
	Desferoxamine (DFO)	Suramin
	Etoposide (VP-16)	Tamoxifen (Nolvadex)
	Flavopiridol (inhibitor of cyclin dependent kinases)	Thalidomide (Thalomid)
	Fluvastatin	Tipifarnib
	GPI 15427 (PARP inhibitor)	Trastuzumab
	Lobradimil	Troglitazone
	Lonafarnib (Sarasar, SCH66336)	Valproic Acid
	Nonsteroidal Anti-Inflamm.Drugs (Celebrex, etc.)	YM155
	OSI-774 (Erlotinib, Tarceva)	ZD1839 (Gefitinib, Iressa)


Noteworthy Protocols
	C5R Protocol	Individualised Therapy


Ongoing Research
	Alternating Electric Fields (TTFields)	Inhibition of Cell Signalling Channels
	Antiangiogenesis	Interferon
	Antisense Therapy	Kinase Inhibitors
	Anti-TNF Treatment	Monoclonal Antibodies
	Apoptosis	Nanoparticles
	Bioreductive Antitumor Agents	Noscapine
	Cancer Stem Cells	Photodynamic Therapy
	Differentiation Agents	Somatostatin
	Drug Delivery	Stem Cells
	Gene Therapy	Survivin
	Hemopexin	Targeted Therapy
	Hyperthermia	Toxin Therapy
	Hypoxia	Tumor Necrosis Therapy
	Immunotherapy


Treatment/Disease Related Complications
	Anticonvulsant Pathology	Multifocal Tumor Recurrences
	Brain Inflammation	Myelosuppression
	Cerebral Edema	Neoplastic Fever
	Cardiological Diseases	Neurologic Complications
	Chemoresistance and DNA repair mechanism	Cancer Pain
	Collateral damage in nontargeted tissues	Obesity
	Chemotherapy-Induced Phatology	Paraneoplastic Neurological Disorders
	Diarrhea	Plateau Waves
	Effects on Liver	Pneumonia
	Endocrine Morbidity	Radiation Related Pathology
	Fatal Outcome	Radionecrosis
	Fatigue	Radioresistance
	Gastric Damage	Secondary Adrenal Insufficiency
	Hydrocephalus	Seizures
	Induced Second Neoplasm	Spinal Cord Compression
	Infections	Spondilodiscitis
	Leptomeningeal Diseases	Surgery Related Pathology
	Long Term Complications	Transplant
	Malnutrition	Thromboembolism
	Miscellany (Hemorrhagic cystitis, etc.)